Nat. Biotechnol. 24, 1181 (2006); published online 5 October 2006; corrected after print 8 November 2006.
In the version of this article initially published, Symphogen's Symplex technology was said on page 1181, paragraph 5, to involve phage display. That is incorrect; it involves direct PCR cloning, expression and screening of antibodies from B lymphocytes. In paragraph 6, line 3, John Haurum was described as Symphogen's Chief Financial Officer; he is the Chief Scientific Officer. In paragraph 6, line 9, “Symphogen has partnered with AstraZeneca,” is incorrect; it has partnered with Stockholm-based Biovitrum.
Additional information
The online version of the original article can be found at 10.1038/nbt1006-1181
Rights and permissions
About this article
Cite this article
Waltz, E. Erratum: Polyclonal antibodies step out of the shadows. Nat Biotechnol 24, 1448 (2006). https://doi.org/10.1038/nbt1106-1448b
Issue Date:
DOI: https://doi.org/10.1038/nbt1106-1448b
